- Details
- In this conversation, Neha Vapiwala joins Alicia Morgans in a conversation on the ECOG-ACRIN EA8191 (INDICATE) phase III trial in progress. In patients with prostate cancer who experience biochemical recurrence, the ECOG-ACRIN EA8191 (INDICATE) trial examines whether patients without PET-detected lesions outside the pelvis benefit from the addition of apalutamide to standard salvage radiotherapy +...
|
- Details
- Amy Moran joins Alicia Morgans in a discussion on the mechanisms of immunotherapy resistance in prostate cancer patients, and how androgens or the androgen receptor (AR) contribute. Amy Moran received a Prostate Cancer Foundation Young Investigator Award for this research which aims to reveal how androgens and AR activity regulate human T cell function and immunotherapy resistance and may reveal n...
|
- Details
- At the 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat Dr Saul Priceman joins Alicia Morgans in a discussion on clinic-ready CAR T cell therapies for Metastatic castrate-resistant prostate cancer (mCRPC) that can overcome the limitations of prior CAR T cell products for prostate cancer. Dr. Priceman highlights the role of PCF's funds in impacting these research efforts. The project...
|
- Details
- In a conversation with Alicia Morgans, Phillip Sutera discusses his work in metastasis-directed therapy (MDT). Dr. Sutera gives a brief overview of the background of the research discussing the association between prostate-specific membrane antigen (PSMA) response and radiographic-progression-free survival among patients treated with stereotactic ablative radiation therapy in oligometastatic castr...
|
- Details
- Samuel Washington joins Alicia Morgans in a conversation on a population-based analysis evaluating geographic variations in the utilization of doublet therapy for metastatic prostate cancer patients. There is strong level-one evidence to support the use of combination therapies, in the form of doublet and triplet therapies in men with metastatic prostate cancer with overall survival benefits demon...
|
- Details
- Josh Lang joins Alicia Morgans in a discussion on the importance of understanding mechanisms of resistance to targeted therapies through the development of novel liquid biopsies of the human tumor microenvironment. Lang highlights his research which looks beyond tissue biopsy to liquid biopsies of cancer cells from a blood draw to inform decision-making. Research funded by the Prostate Cancer Foun...
|
- Details
- Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...
|
- Details
- Vivek Narayan joins Alicia Morgans at ASCO 2022 to discuss his work with CAR T-cell therapies and prostate cancer, the first-in-human study. Using a low-dose escalation approach, Dr. Narayan and his team designed the study safety as the primary objective to evaluate the feasibility of manufacturing and delivering the CAR T-cells. He describes how findings showed both on-treatment toxicity and on-t...
|
- Details
- Alicia Morgans sits down with Charles Ryan to discuss the recent publication of Urologic Oncology: Multidisciplinary Care for Patients, a book she co-edited with Kelly Stratton. Dr. Morgans shares her thoughts on the importance of collaboration across teams in treating patients with GU cancers and provides an overview of key content in the book. Biographies: Alicia Morgans, MD, MPH , Genitourinary...
|
- Details
- Clara Hwang shares an overview of her ASCO 2022 poster session presentation with Alicia Morgans. Dr. Hwang explains how the research was motivated by the known disparities in Black versus white men regarding prostate cancer diagnosis and prognosis. She then describes how this study explored these disparities within the prostate cancer precision medicine space. Biographies: Clara Hwang, MD, Medical...
|